Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novavax, Inc.
Pfizer CEO says that an EUA request for its COVID-19 vaccine is unlikely before late November. Analyst calls Pfizer’s development pace an encouraging sign it could be a more nimble company.
Analysts are confident that Pfizer/BioNTech’s mRNA vaccine will prove its safety and efficacy – but waiting a little longer for more robust data could be for the best.
Updated: a graphic tracker of key developments from the leading vaccine candidates.
As the clock ticks down to the US election day on 3 November, President Trump maintains that the first COVID-19 vaccine emergency use approval is imminent. Meanwhile, Fujifilm Toyama's Avigan is near to Japanese approval.
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- CPL Biologicals Pvt. Ltd. (Joint Venture with Cadila)
- Isconova AB
- Novavax AB